Two Maryland-based companies are racing to get a vaccine for respiratory syncytial virus (RSV) to market–and one just picked up a regulatory boost.
MedImmune, AstraZeneca’s ($AZN) biologics research and development arm, announced on Thursday that the FDA is fast-tracking its RSV vaccine, MEDI8897. It joins Novavax ($NVAX), which received FDA fast-track designation for its candidate in November.
{iframe}http://www.fiercepharma.com/r-d/astrazeneca-s-medimmune-gets-rsv-candidate-fast-tracked{/iframe}